BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 24797746)

  • 1. Autoantibodies in psoriatic patients treated with anti-TNF-α therapy.
    Bardazzi F; Odorici G; Virdi A; Antonucci VA; Tengattini V; Patrizi A; Balestri R
    J Dtsch Dermatol Ges; 2014 May; 12(5):401-6. PubMed ID: 24797746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline anti-dsDNA concentrations and previous treatments predict response to Adalimumab and Etanercept: a retrospective investigation of 146 psoriasis patients.
    Hoffmann JH; Knoop C; Enk AH; Hadaschik EN
    J Dermatol Sci; 2014 Dec; 76(3):180-5. PubMed ID: 25306295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
    Williams VL; Cohen PR
    Int J Dermatol; 2011 May; 50(5):619-25. PubMed ID: 21506984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
    De Rycke L; Baeten D; Kruithof E; Van den Bosch F; Veys EM; De Keyser F
    Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse reactions during biological drug therapy in psoriasis:clinical series and a review of the literature.
    Montesu MA; Addis GM; Satta R; Cottoni F
    G Ital Dermatol Venereol; 2011 Aug; 146(4):273-81. PubMed ID: 21785393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of systemic lupus erythematosus with focal proliferative lupus nephritis during anti-TNF-alpha therapy for psoriatic arthritis].
    Haake H; Köneke J; Amann K; vom Dahl J; Janssen U
    Med Klin (Munich); 2007 Oct; 102(10):852-7. PubMed ID: 17928969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-α antibody-treated patients with inflammatory bowel disease.
    Beigel F; Schnitzler F; Paul Laubender R; Pfennig S; Weidinger M; Göke B; Seiderer J; Ochsenkühn T; Brand S
    Inflamm Bowel Dis; 2011 Jan; 17(1):91-8. PubMed ID: 20564536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
    Bonafede M; Fox KM; Watson C; Princic N; Gandra SR
    Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity.
    Caramaschi P; Biasi D; Colombatti M; Pieropan S; Martinelli N; Carletto A; Volpe A; Pacor LM; Bambara LM
    Rheumatol Int; 2006 Jan; 26(3):209-14. PubMed ID: 15627197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
    Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
    Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-TNF-alpha treatment in rheumatoid arthritis with anti-Ro/SSA antibodies. Analysis of 17 cases among a cohort of 322 treated patients.
    Cavazzana I; Bobbio-Pallavicini F; Franceschini F; Bazzani C; Ceribelli A; Bravi E; Zingarelli S; Caporali R; Cattaneo R; Montecucco CM
    Clin Exp Rheumatol; 2007; 25(5):676-83. PubMed ID: 18078613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/non-case study in a nationwide pharmacovigilance database.
    Moulis G; Sommet A; Lapeyre-Mestre M; Montastruc JL;
    Rheumatology (Oxford); 2014 Oct; 53(10):1864-71. PubMed ID: 24899660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of MGUS in psoriatic patients: a possible undiagnosed event during anti-TNF-α-treatment.
    Prignano F; Pescitelli L; Ricceri F; Ermini A; Lotti T
    J Eur Acad Dermatol Venereol; 2012 Nov; 26(11):1444-8. PubMed ID: 21834947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antinuclear antibodies associate with loss of response to antitumour necrosis factor-alpha therapy in psoriasis: a retrospective, observational study.
    Pink AE; Fonia A; Allen MH; Smith CH; Barker JN
    Br J Dermatol; 2010 Apr; 162(4):780-5. PubMed ID: 19863499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study.
    Fouache D; Goëb V; Massy-Guillemant N; Avenel G; Bacquet-Deschryver H; Kozyreff-Meurice M; Ménard JF; Muraine M; Savoye G; Le Loët X; Tharasse C; Vittecoq O
    Rheumatology (Oxford); 2009 Jul; 48(7):761-4. PubMed ID: 19395543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors.
    Deng A; Harvey V; Sina B; Strobel D; Badros A; Junkins-Hopkins JM; Samuels A; Oghilikhan M; Gaspari A
    Arch Dermatol; 2006 Feb; 142(2):198-202. PubMed ID: 16490847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic disease?
    Kilic O; Kasapcopur O; Camcioglu Y; Cokugras H; Arisoy N; Akcakaya N
    Rheumatol Int; 2012 Sep; 32(9):2675-9. PubMed ID: 21789614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-nuclear antibody positivity and the use of certolizumab in inflammatory bowel disease patients who have had arthralgias or lupus-like reactions from infliximab or adalimumab.
    Verma HD; Scherl EJ; Jacob VE; Bosworth BP
    J Dig Dis; 2011 Oct; 12(5):379-83. PubMed ID: 21955431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Lupus like syndrome induced by treatment with anti TNFalpha (infliximab): report of three cases].
    Benucci M; Nenci G; Cappelletti C; Manfredi M
    Recenti Prog Med; 2008; 99(7-8):363-6. PubMed ID: 18751615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
    Saougou I; Markatseli TE; Papagoras C; Voulgari PV; Alamanos Y; Drosos AA
    Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.